Creo Medical Group PLC represents values such as innovation, integrity, and excellence. The company is dedicated to delivering cutting-edge medical solutions to improve patient outcomes. Creo Medical Group PLC follows a patient-centric approach, ensuring that their products and technologies meet the highest standards of quality and effectiveness. Their corporate philosophy emphasizes the importance of collaboration, research, and development to provide advanced therapeutic solutions in the field of endoscopy and minimally invasive surgery. With a strong focus on continuous improvement and customer satisfaction, Creo Medical Group PLC strives to contribute to the advancement of medical technology for the benefit of patients worldwide.

Creo Medical Group PLC is primarily present in various countries and regions around the world. Some of the key markets where the company operates include the United Kingdom, Europe, Asia-Pacific, and North America. With its global presence, Creo Medical Group PLC caters to a wide range of customers and investors across different geographical locations.

Creo Medical Group PLC has achieved significant milestones since its establishment. Some noteworthy achievements include the FDA clearance for their Speedboat RS2 device, allowing the company to enter the US market and expand its customer base. Additionally, Creo Medical Group PLC received CE Mark approval for its CROMA platform, enabling commercialization in the European market. The company also secured key partnerships and collaborations with renowned medical institutions and professionals, highlighting its commitment to innovation and development in the medical device sector. With these milestones, Creo Medical Group PLC has established itself as a leading player in the field, dedicated to improving patient outcomes through advanced technology.

Creo Medical Group PLC, a leading medical device company based in the UK, was founded in 2003. The company specializes in the development and commercialization of advanced surgical instruments. Creo Medical has a strong focus on non-invasive surgical technologies that provide effective treatments with minimal patient discomfort and enhanced recovery. With a talented team of professionals, Creo Medical has achieved significant milestones in its history, including the successful launch of its flagship device, the CROMA™ Advanced Energy Platform. The company is committed to driving innovation in the medical field, working towards improving patient outcomes and revolutionizing surgical procedures globally. Creo Medical Group PLC continues to grow and establish a strong presence in the market through its dedication to research, development, and commercialization of cutting-edge medical devices.

The main competitors of Creo Medical Group PLC in the market are (insert competitor names here).

Creo Medical Group PLC is primarily active in the medical technology industry.

The business model of Creo Medical Group PLC revolves around developing and commercializing medical devices for surgical endoscopy. Creo Medical specializes in advanced energy devices and aims to provide innovative solutions for minimally invasive procedures, such as radiofrequency ablation and microwave coagulation. By leveraging its proprietary technology, Creo Medical aims to enable healthcare professionals to improve patient outcomes, minimize complications, and reduce healthcare costs. With a focus on enhancing clinical capabilities and expanding its product portfolio, Creo Medical Group PLC continues to drive innovation in the medical device industry.

مُعامل القيمة السوقية إلى الأرباح لـ Creo Medical Group هو ؜-٦٫٥٦.

مُعامِل القيمة إلى المبيعات Creo Medical Group هو ٢٫٢٥.

نقاط جودة AlleAktien لـ Creo Medical Group هي 5/10.

المتوقعة Creo Medical Group الإيرادات هي ٣٩٫٩٦ مليون. GBP.

صافي الربح المتوقعة Creo Medical Group هو ؜-١٣٫٧٢ مليون. GBP.

Creo Medical Group PLC is a British medical technology company that specializes in the development and marketing of advanced medical technologies for endoscopy. The company was founded in 2003 and is headquartered in Chepstow, Wales.

يوزع Creo Medical Group أرباحًا قدرها 0 GBP من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Creo Medical Group في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـCreo Medical Group هو GB00BZ1BLL44.

رمز WKN لـ Creo Medical Group هو A2DH40.

الرمز المُختصر لـ Creo Medical Group هو CREO.L.

خلال آخر 12 شهراً، دفعت Creo Medical Group توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Creo Medical Group خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 GBP.

نسبة توزيعات الأرباح الحالية لـ Creo Medical Group هي .

Creo Medical Group يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Creo Medical Group دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 GBP. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Creo Medical Group يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 GBP من Creo Medical Group المُعلن عنها في ١١‏/٩‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ١١‏/٩‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ١١‏/٩‏/٢٠٢٤.

في العام 2023، وزعت Creo Medical Group 0 GBP كأرباح أسهم.

يتم توزيع أرباح Creo Medical Group بالعملة GBP.